register

News & Trends - Pharmaceuticals

First-in-class oncology drug candidate licensed by Aussie pharma

Health Industry Hub | April 21, 2021 |
[Total: 1    Average: 5/5]

Pharma News: An Australian oncology-focused drug development company entered into a worldwide exclusive licensing agreement and a master services agreement with Evotec, a leading European drug company, to develop, manufacture, and commercialise EVT801, a small-molecule, first-in-class oncology drug candidate.

EVT801 was originally discovered by Sanofi and was developed through a partnership between Sanofi and Evotec.

Kazia CEO, Dr James Garner, commented “We are delighted to add this tremendously exciting new compound to the Kazia pipeline. Evotec have done first-class work in the early development of EVT801, and the preclinical data package is exceptionally strong. We intend to fast track a phase I clinical trial of the drug, which we expect to commence in CY2021.”

He added, “As we have built Kazia over the past five years, our strategy has been to assemble a portfolio of world-class development candidates through in-licensing. The EVT801 transaction is wholly consistent with that strategy. We have demonstrated, through the paxalisib program, our ability to add value to a development candidate, and we intend to similarly accelerate EVT801 via a rich and innovative development program.”

EVT801 is a small molecule inhibitor of vascular endothelial growth factor receptor 3 (VEGFR3) and is administered orally.

It is hoped that administration of EVT801 may help to sensitise tumours to immuno-oncology therapies such as MSD’s Keytruda (pembrolizumab) and Bristol-Myers Squibb’s Opdivo (nivolumab) and thereby extend their use.

Kazia expects to launch a phase I clinical trial in CY2021. The initial exploratory indications for EVT801 include renal cell carcinoma (kidney cancer), hepatocellular carcinoma (liver cancer) and soft tissue sarcoma.

Under the terms of the agreement, Kazia will pay Evotec an upfront of €1 million (AU$ 1.6 million), contingent milestones of up to €308 million (AU$ 480 million) related to achievement of clinical, regulatory, and commercial outcomes over the lifetime of the drug, and a tiered single-digit royalty on net sales.


About the author

About the author

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Nam luctus finibus scelerisque. Nunc bibendum ipsum sed augue fringilla fringilla. Nullam at consectetur leo. Praesent viverra rutrum porta. Quisque vitae mi vel purus vulputate tincidunt. Class aptent taciti sociosqu ad litora torquent per conubia nostra, per inceptos himenaeos. Suspendisse et mi quis nisi rhoncus feugiat at ac tellus. Sed aliquam sodales nulla ac auctor. Sed pretium lobortis purus accumsan ullamcorper. Phasellus sodales vel odio in lobortis. Duis maximus sagittis bibendum. Interdum et malesuada fames ac ante ipsum primis in faucibus. Nunc dictum tincidunt ipsum in vestibulum. Donec ut sem consectetur, aliquam quam vitae, pharetra orci. Nam egestas non velit eu rhoncus. Duis congue neque non lacus tincidunt porta. Vestibulum ultricies pulvinar sem, molestie congue dui aliquet non.
  • Ut imperdiet leo id lorem fermentum consectetur.
  • Ut vitae orci et dui varius tincidunt.
  • Ut id magna non libero vestibulum pharetra ac faucibus nulla.
Aliquam erat volutpat. Vestibulum vitae varius diam. Nulla eget congue ante. Nunc ullamcorper sagittis augue vel dictum. Mauris finibus nibh ut pulvinar auctor. Vestibulum ut faucibus nisi. Orci varius natoque penatibus et magnis dis parturient montes, nascetur ridiculus mus. Quisque porta tortor ac justo malesuada elementum. Nulla tellus ante, cursus nec ex sit amet, suscipit bibendum arcu. Duis posuere orci dui, et mollis enim dictum at. Sed ullamcorper, sapien ut vulputate viverra, sem purus porttitor tellus, nec mattis mauris ligula sed risus. Nulla sagittis id ipsum eu mattis. Link to full profile

Digital & Innovation

Healthcare Technology Digital Innovations - Genomics industry making headlines at HealthData21

Genomics industry making headlines at HealthData21

Health Industry Hub | May 13, 2021 |

Australia’s new genomics industry alliance Industry Genomics Network Alliance (InGeNA) will bring together representatives from the key sectors of diagnostics, […]

More


News & Trends - Medical Technology

MedTech News - B. Braun launches renal care centre in NSW and QLD

B. Braun launches renal care centres in NSW and QLD

Health Industry Hub | May 13, 2021 |

MedTech News: B. Braun, one of the world’s leading providers of medical devices, dialysis products and renal care services has […]

More


News & Trends - Pharmaceuticals

Pharma News - BMS immunotherapy combo approved in aggressive thoracic cancer

BMS immunotherapy combo approved in aggressive thoracic cancer

Health Industry Hub | May 13, 2021 |

Pharma News: Bristol-Myers Squibb (BMS) welcomed the Therapeutics Goods Administration (TGA) registration of its immunotherapy combination drugs for the first-line […]

More


News & Trends - Pharmaceuticals

Pharma News - GSK bridges the skills gap between academia and pharma industry

GSK bridges the skills gap between academia and pharma industry

Health Industry Hub | May 13, 2021 |

Pharma News: Six PhD graduates have recently traded in their lab coats for laptops after landing a place in a […]

More